Genmab

	17/3 20:00 af E L	anyway, very promising data for Rina-S better then what we saw at ESMO
	17/3 19:59 af E L	@M_T_A that's the point; genmab had not disclosed the targets. but since they seem to stop with the trial , that doesn't matter that much anymore
	17/3 18:34 af ProInvestorNEWS	Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer (link)
	17/3 18:27 af The Joker	"The antitumor activity observed in the dose expansion cohort continues to demonstrate the potential for a much-needed treatment option for patients with PROC, who have historically had poor prognosis. I am hopeful that further exploration of Rina-S will lead to advancements in the treatment landscape." said Elizabeth Lee, M.D., a medical oncologist in the gynecologic oncology program at Dana-Farber.
	17/3 18:26 af The Joker	1 out of 10 patients experienced disease progression and the median duration of response (mDOR) was not reached (95% CI: 40.14-NR). The data are from the dose expansion cohort of the multi-part study evaluating the safety and efficacy of Rina-S as a single agent in solid tumors that are known to express FRα and were presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women's Cancer® (SGO) in Seattle, Washington.
	17/3 18:26 af The Joker	Genmab A/S (Nasdaq: GMAB ) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug conjugate (ADC) that showed Rina-S 120 mg/m2 every 3 weeks (Q3W) resulted in a confirmed objective response rate (ORR) of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer (OC) patients regardless of FRα expression levels. With a median on-study follow-up of 48 weeks,
	17/3 18:23 af M_T_A	Rina-S data! 55% ORR, mDOR not reached!
	17/3 18:22 af M_T_A	@E L which targets? i dont see any?
	17/3 18:03 af E L	only 3 patients treated; can't be too costly... they said they would be ruthless cutting programs that don't hold up and they are i guess
	17/3 17:50 af gentogen	The positive take 2: Laser Sharp Focus
	17/3 17:19 af Vitus	Nu må du bruge din fantasi lahn1 :-)
	17/3 17:04 af E L	the positive take: we don't really have to guess about the target anymore for GEN1078... (link)
	17/3 15:37 af Sukkeralf	Valby
	17/3 15:10 af lahn1	Hvor er hjem ? :-)
	17/3 11:16 af Vitus	Hvor langt mon der er hjem for Genmab ?
	15/3 22:11 af Sukkeralf	Nurix har et par BTK degraders i udvikling og ved deres post ASH præsentation sagde en læge, at synes det kunne være spændende at se en BTK degrader gøre det grove arbejde i CLL og så ryde de sidste rester væk med et CD20/CD3 BsAb - så mon ikke vi får det at se før eller siden. Beigene har dog overhælet Nurix med deres BTK degrader, så måske det er dem man skulle holde øje med.
	15/3 22:09 af Sukkeralf	Nej for det er small molecules, så det gør de ikke. Et selskab som Nurix Therapeutics, som arbejder med degraders, har teamet op med Pfizer (Seattle Genetics) og laver DACs - altså hvor de konjugerer protein degraders til antistoffer, så man i princippet får dobbelt præcisions terapier, hvilket gerne skulle vise sig at være endnu mere sikre end ADC og måske også mere potente.
	15/3 18:19 af JStudsgaard	Jeg var i tvivl om hvorvidt Genmab arbejdede med teknologien. Men det kan jeg indirekte læse at de ikke gør. Tak @ Sukkeralf
	15/3 16:44 af Sukkeralf	Det kan også være vi i fase III når flere patienter indrulles ser et mere mudret billede - det endte Sutro i hvert fald op med at kæmpe med.
	15/3 16:43 af Sukkeralf	Solsen vedrørende terapeutisk vindue for RinaS, så kan jeg bare huske ORR for 100 mg var ret lav i forhold til valget dosis på 120 mg - og at bivirkningsprofilen i 140 mg var slem. Selvfølgelig baseret på forholdsvis få patienter, men måske har man ramt sweet spot ved dosis på 120 mg, hvor effekten er god og bivirkningsprofilen tålelig.
	15/3 16:29 af Sukkeralf	Håber de over tid kaster sig over DACs i samarbejde med et degrader selskab, men det må tiden jo vise.
	15/3 16:29 af Sukkeralf	Det har Genmab umiddelbart ikke noget at gøre med - måske Epkinly snart skal kombineres med en BTK degrader i CLL.
	15/3 16:28 af Sukkeralf	JStudsgaard - mener du protein degraders i henhold til dit spørgsmål om PROTACs?
	15/3 14:51 af Solsen	Der faldt lidt bogstaver ud på Benchmark til RinaS…

	15/3 14:51 af Solsen	Tror man skal se lidt resultater fra PROTAC før man kan sige noget om det.
	15/3 14:49 af Solsen	Bencmark til RnaS (link)
	15/3 14:24 af JStudsgaard	Hvor står Genmab ifht. PROTACs?
	15/3 09:10 af E L	yes, or this one for example (link)
	14/3 22:05 af lahn1	This one EL? (link)
	14/3 20:22 af E L	I remember an article with Hexabody applied to CD20, but I am sure there will be others
	14/3 20:12 af E L	I put my answer in the wrong place (again) lol @Sukkeralf 14/3 2025 17:53 af E L true. but the fact that they are hoping to bring several new candidates to the clinic is promising ; they wouldn't do that if they don't see the benefit / validation. crossing fingers ;)
	14/3 19:13 af lahn1	Do we know what Hexabody candidates didn’t make it to the clinic ?
	14/3 18:40 af Hugininvest	Lad os bare få rundt regnet 20 dage som i dag. Så er vi ved at se en fair kurs. Go weekend :-)
	14/3 17:55 af wisuwa	Kunne Alligator Bioscience med Mitazalimab (til bugspytskirtelkraft) i fase 2 med stærke 24 måneders read-out være en opkøbskandidat? Pt. handles selskabet til sølle 91 millioner DKK…
	14/3 17:38 af Sukkeralf	On the other hand none of Genmabs hexabody candidates have gone far in clinical trials - and not that many companies go after the CDC mecanish so still a lot to prove I guess.
	14/3 17:33 af E L	What it has given us is a higher degree of confidence that this technology, where a single point mutation is able to enhance Complement-dependent cytotoxicity and is able to overcome to a degree the expression of complement inhibitory proteins. And this is very important as we think about other disease areas and other targets.
	14/3 17:33 af E L	So there is a little bit of a high-end neutropenia rate that is arguably related to the mechanism, but also arguably related to the increased efficacy because the phenomenon of neutropenia and B-cell depletion, while ill understood has been observed in every single B-cell redirected therapy. The more modifications to B-cell depletion is, the more enhanced is the neutropenia. . And that's, I think, the main safety observation on HexaBody-CD38.
	14/3 17:32 af Sukkeralf	(link)
	14/3 17:31 af E L	And CD38, to remind everyone, is arguably one of the dirtiest targets out there. It's expressed in a lot of cells.
	14/3 17:30 af E L	And what the data clearly shows is that with the single point mutation, you get [ ] imbalance a significantly meaningful enhancement of the depth of response, meaning we captured a larger portion of tumor cells with CD38 because there is an inter-patient variability of CD38 expression on the myeloma cells.
	14/3 17:29 af E L	Number one, and it's just like remind ourselves of what the challenge and what the objective was. The objective was with a single point mutation to create an asset that then would hexamerize. And through the hexamerization with enhanced CDC and as we talked about, what that would do is it will lower the threshold of CD38 required on the cells to then be sensitive to CDC.
	14/3 17:29 af E L	on the your level of confidence in your HexaBody technology platform : It's actually much higher because we think that this data shows that the HexaBody platform is clinically validated to lead to a more effective therapeutic.
	14/3 17:28 af E L	So we think this is a very promising platform, Alistair. And then more to come in the coming years. We have a number of very exciting preclinical program which are slotted to move to the clinic, where we actually hope to break paradigms basically, moving into new areas where antibodies are not very successful in tumor therapy. But with this modification, I think could be very successful. So more to come.
	14/3 17:27 af E L	a few more snippets from this week's call - we are actually working preclinically with HexaBody programs for I&I. And so we think that this is actually an excellent technology platform which is validated here clinically. And we don't think that the safety aspects will be very much impacted by the HexaBody modification. So no, I think this trial and this data shows that there is a clear advantage in potentiating the killing activity of antibodies via HexaBody mutation.
	14/3 16:57 af E L	since we spoke about it this morning; just to repeat Jan: 'There will be a data on the endometrial cancer in the first half of this year at a major cancer conference. ' (for Rina-S)
	14/3 14:56 af JKY_VH	Tak ilm Solsen;-)
	14/3 13:53 af Teller	Genmab er et godt køb pt. og skal op.
	14/3 13:52 af Solsen	Den store depression overstået. God weekend !
	14/3 13:45 af Legolas23	Fik vi lige kickstartet tilbagekøbsprogrammet der...
	14/3 12:41 af ProInvestorNEWS	Genmabs kursmål skæres til hos Nykredit efter Hexabody-skuffelse (link)